This test determines an individual’s genetic risk assessment associated with the Apolipoproein E gene. ApoE is involved in the metabolism of cholesterol and triglycerides, and variants in this gene can have clinically relevant implications for disease risk as well as one’s response to statin therapy, dietary fat and other risk factors (e.g. smoking and alcohol consumption). Approximately 45% of individuals carry one or more o f the high risk variants within the ApoE gene. The results of the genotyping of Apoliporotein E have important implications in the treatment strategies for patients in reducing cardiovascular disease risk.
The APOE-e4 allele, present in approximately 10% to 15% of people, increases the risk of Alzheimer’s disease and lowers the age of onset. Having one copy of e4 (e3/e4) can increase your risk by 2-3 times, while having two copies (e4/e4) can increase your risk up to 12 times.
To find out more regarding how to reduce this risk, go HERE.
Six possible ApoE genotypes exist: e2/e2, e2/e3, e2/e4, e3/e3, e3/e4 and e4/e4.
More Genetic Testing: